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Introduction: A handful of studies have reported outcomes with CyberKnife radiosurgery (CKRS) for the treatment
of trigeminal neuralgia. However, the follow-up has been short with no minimum follow-up required and have
included patients with short duration of symptoms. Here we report our institutional experience on patients with a
minimum follow-up of 1 year and a median follow-up of 28 months (mean 38.84 months).
Methods: Twenty-five patients with medically and surgically intractable TN received CKRS with a mean marginal
radiation dose of 64 Gy applied to an average isodose line of 86% of the affected trigeminal nerve. Follow-up data
were obtained by clinical examination and telephone questionnaire. Outcome results were categorized based on
the Barrow Neurological Institute (BNI) pain scale with BNI I-III considered to be good outcomes and BNI IV-V
considered as treatment failure. BNI facial numbness score was used to assess treatment complications.
Results: A large proportion of patients (42.9%) reported pain relief within 1 month following CKRS treatment. The
mean time to recurrence of severe pain was 27.8 months (range 1–129 months). At median follow-up of 28 months
(mean 38.84 months), actuarial rate of freedom from severe pain (BNI ≥ III) was 72%. At last follow-up 2 (8%)
patients had freedom from any pain and no medications (BNI I) and the majority (48%) had some pain that was
adequately controlled with medications. Seven patients (28%) had no response to treatment and continued to
suffer from severe pain (BNI IV or V). Patient’s diabetic status and overall post-treatment BNI facial numbness scores
were statistically significant predictors of treatment outcomes.
Conclusion: CKRS represents an acceptable salvage option for with medically and/or surgically refractory patients.
Even patients with severely debilitating symptoms may experience significant and sustained pain relief after CKRS.
Particularly, CKRS remains an attractive option in patients who are not good surgical candidates or possibly even
failed surgical therapy. This data should help in setting realistic expectations for weighing the various available
treatment options.
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Trigeminal neuralgia (TN) is a debilitating condition char-
acterized by agonizing, paroxysmal, and lancinating pain
[1]. Although the incidence of TN was thought to be less
than 5 per 100,000 patient-years based on epidemiologic
data from Olmstead County, Minnesota [2] more recent* Correspondence: WCJ4@gunet.georgetown.edu
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unless otherwise stated.studies have found TN to be much more common with
incidence rates ranging from 12.6 to 28.9 per 100,000
patient-years [3]. Most patients suffering from trigeminal
neuralgia (TN) respond to medical or surgical treatment,
nonresponders have limited options [4]. Second-line treat-
ment modalities are utilized in patients whose symptoms
are intractable or who cannot tolerate medication. These
include surgical procedures such as microvascular decom-
pression (MVD), and ablative procedures such as percutan-
eous balloon microcompression, radiofrequency rhizotomy,
glycerol rhizolysis, and radiosurgery. While GammaKnife
Radiosurgery has been shown to be effective in obtainingThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinical demographic characteristics in 36
patients with medically intractable trigeminal neuralgia





Mean age (range) 65 (43–86)
Prior surgery 20 (80.0%)











Multiple sclerosis 4 (16.0%)
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there have been only a handful of reports with the
CyberKnife Radiosurgery (CKRS) system (Accuray, Inc.,
Sunnyvale, CA) [5-7]. The ease of administration and
non-invasive nature of this non-isocentric treatment
modality makes it an appealing procedure for patients
and treating radiosurgeons. Here we present the longest
institutional outcomes reported to date for CKRS in the
treatment of TN. Our analysis also represents the only
one in which the inclusion criteria are limited to patients
with a pretreatment BNI of IV or V and with a minimum
follow-up of 12 months.
Materials and methods
Patient characteristics
After institutional review board (IRB) approval by
Georgetown University Hospital IRB, patient demo-
graphic characteristics, clinical presentation, treatment
history, and the radiosurgical modality were retrospect-
ively reviewed.
Patients were also followed-up by a telephone question-
naire that was conducted by a medical personnel who
were not involved in treatment. Patients were questioned
about the time to the onset of pain relief, the degree of
pain relief and treatment complications. Based on the
Barrow Neurological Institute (BNI) score for TN, we
classified pain relief after treatment into five grades. A
BNI I score corresponded to complete pain relief without
medications; BNI II score, some pain but not requiring
medications; BNI III score, some pain but adequately
controlled with medications; BNI IV score, some pain not
adequately controlled with medication; and BNI V score,
severe pain or no pain relief. The BNI facial numbness
score was used to assess complications. A BNI I score
corresponded to no facial numbness; BNI II score, mild
facial numbness, not bothersome; BNI III, facial numb-
ness somewhat bothersome; and BNI IV score, facial
numbness, very bothersome.
Between July 2002 and February 2013, 30 patients with
severe refractory TN and with minimum follow-up of
12 months underwent CK at our clinic. Five patients had
no follow up information and could not be contacted by
phone so they were excluded for a final sample size of
25 patients. Indications for CK included intractable pain,
with a pretreatment BNI score or IV or V, refractory to
standard medications and failure of previous invasive
procedures. The median follow-up was 28 months (range
12–129 months; mean 38.84 months) and a summary of
patient characteristics is provided in Table 1.
Radiosurgery technique and dosimetry
The CKRS system (Accuray, Inc., Sunnyvale, CA, USA)
uses a 6-MV X-band linear accelerator (LA) mounted on
a fully articulated robotic arm. During treatment, twoorthogonally positioned x-ray detectors provide real-time
imaging of bony anatomy allowing for intrafraction move-
ment correction. Treatment was generally administered
on an outpatient basis with each treatment lasting ∼ 45–
90 min.
Patients were immobilized in the supine position with
an Aquaplast facemask (WRF/Aquaplast Corp., Wyckoff,
NJ, USA). All patients underwent an iopamidol-enhanced
CT cisternography with 1.25-mm contiguous slices was
used to visualize the segment of the trigeminal nerve in
the prepontine cistern. A lumbar puncture was performed
to inject 10 mL to 12 mL of contrast material. The trigem-
inal nerve was readily identified on the planning worksta-
tion and a segment of the nerve was marked as the target
(mean volume range, 25–71 mm3). The target included
the cisternal segment of the trigeminal nerve extending to
the gasserian ganglion. The radiation oncologist, neuro-
surgeon, and radiation physicist performed tumor delinea-
tion, dose selection, and planning. Inverse planning was
used to determine the dose to the target volume while
minimizing the dose to normal tissue. A mean marginal
prescription dose of 64.12 Gy (range, 60-80Gy) was used
over the course of this series. The average prescription
isodose line was 86%, whereas the dose at the edge of
the brainstem was kept to less than 30% of isodose line
touching the brain stem, which gives about 22.5 Gy to
the brain stem. Figure 1 shows a composite of the treat-
ment. Figure 1 depicts a representative radiosurgical plan
for trigeminal neuralgia.
AB
Figure 1 Example of CyberKnife radiosurgery plan for trigemial neuralgia. A. Screen shot taken from the CyberKnife (Accuray, Inc.,
Sunnyvale, CA) treatment planning workstation depicting a representative radiosurgical plan for trigeminal neuralgia. Yellow and brown contours
refer to the brainstem and temporal lobe, respectively. B. Higher magnification image illustrating the dose distribution within the target volume.
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Treatment outcomes were assessed by patient self-reports
of pain control and medication usage at last followup. A
pain-free outcome was defined as BNI pain score I and
pain relief or good outcome was regarded as maintaining
a BNI pain score III or better without requiring further
surgery. Treatment failure was defined as pain returning
to a BNI level of IV or V, or the patient undergoing an
invasive surgical procedure due to uncontrolled pain. A
recurrence was defined as a relapse to a previous lower
level after attainment of any higher level of pain relief.
Patients reported the time interval for a response and pain
recurrence after CK. The date of treatment failure was
considered to be the date at which pain relief became a
BNI IV or V score.
Time to BNI class IV to V pain relapse was calculated
with the Kaplan-Meier method. Log-rank tests were per-
formed to determine statistical differences between pain
relapse curves. We conducted a univariate analysis of
several factors hypothesized to influence or predict
successful treatment, using Cox regression analysis:
age, gender, side of pain, duration of symptoms, prior
surgery, diabetic status at diagnosis, pretreatment facial
numbness, and new facial numbness. A p value <0.05
was accepted as statistically significant. All statistical
calculations were performed using SPSS software, version
13.0 (SPSS, Inc., Chicago, IL, USA).
Results
Pain relief after CKRS
A large proportion of patients (42.9%) reported pain relief
within 1 month following CKRS treatment. NineteenFigure 2 Kaplan-Meier curve for time from CyberKnife radiosurgery (C
relapse (i.e., freedom from severe pain).percent of patients reported relief within 6 months of
treatment and another 19% reported relief no relief of
symptoms. In 14.3% relief was experienced within 3 months
from treatment. The median time to recurrence of severe
pain was 19 months (mean 27.8 months; range 1–129
months).
Results of Kaplan–Meier analysis of response time after
CKRS are displayed in Figure 2. At median follow-up of
28 months (mean 38.8 months), actuarial rate of freedom
from severe pain (BNI ≥ III) is 72% (Figure 2). Actuarial
median time to return of severe pain was not reached.
The patient responses at last follow-up, as determined
using the BNI pain intensity scoring system, are listed in
Table 2. At last follow-up 2 (8%) patients had freedom
from any pain and no medications (BNI I) and the major-
ity (48%) had some pain that was adequately controlled
with medications. Seven patients (28%) had no response
to treatment and continued to suffer from severe pain
(BNI IV or V).
Treatment related complications
The majority of the patients (18 or 72%) did not experi-
ence any new bothersome post-treatment facial numbness
(Table 2, bottom row). Two patients developed new
somewhat bothersome facial numbness (BNI III) and
no patients developed any new very bothersome facial
numbness (Table 2, bottom row). Indeed, two patients
reported improvement in her facial pain from very
bothersome facial numbness to no facial numbness
(BNI I). Kaplan Meier analysis shows an actuarial rate
of improvement of facial numbness of 83% at a median
follow-up of 28 months (mean of 38.4 months) (Figure 3).KRS) to Barrow Neurologic Institute (BNI) class IV to V pain
Table 2 Pain response (top 5 rows) and development of






BNI I 2 (8)
BNI II 4 (16)
BNI III 12 (48)
BNI IV 3 (12)







BNI I-II 20 (80) 18 (72)
BNI III 2 (8) 5 (20)
BNI IV 3 (12) 2 (8)
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eye syndrome).
Prognosticators
Univariate analysis for previously published prognostica-
tors of treatment failure is shown in Table 3. Patient’s
diabetic status is shown to be a negative prognostic indi-
cator of good outcome (p = 0.05; Table 3). Additionally,
a statistically significant correlation is found between
overall status of post-treatment BNI facial numbness score
and good outcome (Table 3). Patients with an overall
bothersome post-treatment BNI facial numbness score
(BNI scale III-IV) had improved treatment outcomes
(Table 3). There were no other statistically significant
prognosticators of outcome (Table 3).Figure 3 Kaplan-Meier curve for time from CyberKnife radiosurgery (C
numbness score.Discussion
Prior studies have reported favorable treatment response
rates for CKRS treatment of medically intractable TN
with relatively rapid response rates on the scale of a few
months and in some studies a few weeks [5-10]. Follow-
up in these studies though have been variable between
11 months to over 3 years. This has lead to discrepancies
in reported long-term treatment outcomes as several of
these studies have observed that the pain relief experi-
enced after CKRS declines over time. Additionally, prog-
nostic factors associated with treatment response have
yet to be consistently identified.
In the present study, we report our institutional data
on pain outcomes and side effects from CKRS for the
treatment of TN with a minimum follow-up of 12 months.
In our series, 81% of patients responded to treatment with
improvement in TN pain to non-severe levels (BNI III or
less), which is consistent with previous studies reporting
rates between 67% [10] and 92% [7]. However, our series
has been the only one to limit the patient population to
patients with severe pain (BNI IV or V) and comprise
mostly of patients with surgically intractable TN (80%).
Previous studies have observed that patients with
surgically intractable TN and those with severe pain
undergoing CKRS tend to have significantly worse
outcomes than those who are surgically naïve do [5].
Unexpectedly though, prior surgery for TN was not a
negative prognostic factor for treatment success in our
series. Thus, it is unclear whether the characteristics of
our patient series may explain why we did not achieve
as high as response rates as some other studies examin-
ing CKRS for TN.KRS) to improvement in Barrow Neurologic Institute (BNI)
Table 3 Summary of various prognosticators and
development of treatment failure (BNI IV-V)
Variable Good outcome Treatment failure P-value
No of patients 18 (72%) 7 (28%) 0.05
Gender
Male 10 3 0.51
Female 8 4
Age
≥70 years 7 3 0.81












>8 years 12 4 0.74
<8 years 6 3
Dose
60 Gy 14 5 0.68
>60 Gy 4 2
New Bothersome 0.20





I-II 10 7 0.04
III-IV 8 0
Prior Surgery
Yes 13 4 0.40
No 5 3
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tients noted improvement in symptoms within 1 month
and all reported improvement within 6 months. Villavicencio
et al. reported a mean latency to response of 2 weeks in
a series of 95 patients [10] and a smaller study reported
a mean latency to response of 2.4 days in a series of 13
patients [7]. Other groups, however, have reported mean
latencies to response more consistent with our findings
(1.92 months and 5.2 weeks in [5,9], respectively). The
differences in our results with some of these studiesmay reflect our higher incidence of surgically intractable
TN and our inclusion of patients who only had severe
pain (BNI IV or V) pretreatment. Nonetheless, the short
duration of response latency period between this study
and others emphasizes the importance of discussing fur-
ther treatment options in patients who have not achieved
pain relief within 6 months.
Additionally, our long-term results also are consistent
with other studies reporting long-term data. Our actuarial
freedom from severe pain rate was 72% at 3.2 years. Other
studies have reported actuarial or observed rates of sus-
tained pain relief between 50 to 80% at around 3 years
follow-up [9,10]. Thus, our results add further weight
to the findings of other studies that CKRS for TN has
the potential for sustained significant pain relief. In con-
trast to other studies though, the mean time to recurrence
of severe pain in our patients was 27.8 months, which
appears to be much longer than those of other studies
reporting recurrence times between 9 and 18 months. It is
unclear as to why our mean time to recurrence of severe
pain was such longer than other reported rates. Possibly,
differences in our patient population (i.e. higher propor-
tion of surgically intractable patients, inclusive of only
patients with BNI IV and V pain, younger patients) may
explain this discrepancy.
A common complication associated with CKRS for TN,
which was experienced by a few patients in this series, is
the development of facial numbness. Previous studies have
reported variable rates of bothersome facial numbness
post-treatment ranging from no patients [6] to over 40%
of the patients [9]. A consistent observation is that higher
maximal and marginal doses are associated with higher
incidence of facial numbness, though they are also
associated with increased treatment response and sus-
tained pain relief as well [11]. We observed this in our
series as well. The amount of radiation delivered to the
brainstem also is known to play a large role in the
development of post-treatment facial numbness. In our
study, we limited brainstem radiation to 22.5 Gy and
our average marginal dose was 64.12 Gy. At last follow-
up, only 2 patients reported the development of or
worsening of facial numbness to bothersome levels.
This rate is consistent with previous studies utilizing
treatment doses similar to ours (Adler et al. [5] – 15%
BNI III or greater with marginal of 58.3, Villavencencio
et al., 2007 – 28% BNI III or greater with marginal of
60 [10]). Fariselli et al. [6] who reported that no patient
experienced the development of bothersome facial numb-
ness limited their brainstem radiation dose to 14 Gy.
Thus, limiting the radiation dose to the brainstem and
the marginal dose likely would have reduced the rate of
developing facial numbness post-treatment in our series.
However, it likely would have also reduced the treatment
response.
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patients had significantly worse pain outcomes after
CKRS for TN than patients who did not have a history
of diabetes. In our series, 3 of the 5 diabetic patients
experienced treatment failure (BNI of IV or V at last
follow-up), whereas, only 4 of 20 non-diabetic patients
experienced treatment failure. Another study examining
factors associated with the durability of pain relief after
CKRS for TN also reported that diabetes appeared to be
a negative prognostic indicator [11]. The exact mechan-
ism by which diabetic status affects pain outcomes after
CKRS for TN pain is unknown. Though one may specu-
late that the impaired healing capability of diabetics or
pre-existing neuropathy may contribute to worse out-
comes or more severe disease, further studies examining
this relationship are warranted. Other prognostic factors
examined other than diabetes and facial numbness such
as multiple sclerosis, age, gender, laterality of pain, dur-
ation of symptoms or radiation dose did not appear to be
prognostic of pain outcome.
Lastly, SRS has long been reserved for TN patients
who are not surgical candidates or have comorbidities
conferring them a shorter life expectancy. However, a
recent study suggested that CKRS might be preferable to
surgical therapy, in particular MVD, in certain circum-
stances due to its economic benefits. Tarricone et al.
reported that CKRS proved to be more cost-effective
than MVD yet possessed equivalent clinical effectiveness
as MVD did [12]. These authors’ analyses revealed a cost
difference of 2,250 Euros, which they attributed mostly
to the cost of the surgical procedure and the cost of the
hospital stay for an MVD. Long-term pain control past
6 months though was not included in their analysis and
CKRS has yet to demonstrate in any series the same
sustained clinical effectiveness as MVD over several years.
Nevertheless, given the successful long-term results ob-
tained in our series, CKRS appears to be an attractive
option that is clinically effective, sustained and economic.
There are several limitations to this study. The small
sample size and retrospective nature of this study design
limit the power of our outcome observations. Addition-
ally, although pain intensity and numbness scales are
validated tools for the quantification of pain and numb-
ness, they are subjective outcome measures because they
are dependent on personal interpretations and variation.
The results of this study should, however, help clinicians
provide important information to patients so they can
have realistic expectations and be able to weigh the risks
and benefits relative to the various available treatment
options.
Conclusions
CKRS is a safe, effective, minimally invasive and poten-
tially cost-effective treatment modality for patients withmedically intractable TN or those who are ineligible or
refuse open surgery. Our results demonstrate that a
CKRS treatment is associated with good outcomes in
the majority of patients with sustained relief of TN pain
in most responding to therapy. Our observations also
further support the relationship between the development
of facial numbness and treatment success and suggest that
diabetic status might be a negative prognostic factor in
response to CKRS for TN.
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